MAI Capital Management’s Spyre Therapeutics SYRE Stock Holding History

MAI Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13	Closed	-$656	–	4425
2026 Q1	$656	Buy	+13	New	+$490	﹤0.01%	4322

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

MAI Capital Management's SYRE Position: Q2 2026 in Review

MAI Capital Management sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 13 shares — an estimated $656 sold.

MAI Capital Management first reported a position in SYRE in Q1 2026 and held it in 1 quarter. The position peaked at $656 in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

MAI Capital Management reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 13 Spyre Therapeutics shares in Q2 2026, an estimated $656.
MAI Capital Management first reported a position in Spyre Therapeutics in Q1 2026 and held it in 1 quarter.
MAI Capital Management's Spyre Therapeutics position peaked at $656 in Q1 2026.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.